Mesutoclax is a novel, orally bioavailable BCL2 selective inhibitor. BCL2 is an important regulatory protein in the apoptosis pathway, and its abnormal expression is associated with the development of ...

SOLARA is a global, open label, Phase 1/2 clinical trial assessing the safety, efficacy and tolerability of BH-30643 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) ...

JERSEY GPs have sounded the alarm about the “significant clinical risks” that come from sourcing weight‑loss drugs online without medical supervision – warning that these “unregulated products” could ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

First Patient Dosed in Beckley Psytech’s International Phase IIb Study of BPL-003, a Novel Synthetic Intranasal Formulation of 5-MeO-DMT, for Treatment Resistant Depression (TRD) ...

Akeso, Inc. (9926.HK) (Akeso or the Company) announced the enrollment and dosing of the first patient in the pivotal Phase ...

--Lipocine Inc., a biopharmaceutical company focused on treating Central Nervous System disorders by leveraging its proprietary platform, today announced that study enrollment is complete and the ...

First-in-human trial of Capricor’s StealthX™ vaccine initiated under HHS’s Project NextGenTrial conducted and funded by the ...

The study will assess the efficacy and safety of zorevunersen compared to sham over a 52-week treatment period.

Cyte initiates patient dosing in a new trial for famzeretcel, aiming to transform treatment options for retinitis pigmentosa.

Trade News Published: 24 September 2005 Showcase New pre-dosed mixing capsule British Dental Journal 199, 380 (2005) Cite this article ...